InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ MOU with Rain Cage Carbon to Develop Fullerene-Based Medical Contrast Agents from Carbon Capture of Hydrocarbon Exhaust Systems
October 26 2022 - 8:12AM
Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has signed a
memorandum of understanding with Rain Cage Carbon to develop
fullerene-based contrast agents. Rain Cage Carbon, a private carbon
capture company located in Calgary, has a proven technology that
removes CO2, along with other pollutants from hydrocarbon exhaust
systems.
A Media Snippet accompanying this announcement is
available by clicking on the image or link below:
For more information, please view the
InvestmentPitch Media video which provides additional information
about this news and the company. Brent Willis, President and CEO of
Voyageur has added his video comments about the news release. The
video is available for viewing on
“InvestmentPitch” and on
“YouTube”. If these links are not enabled, please
visit www.InvestmentPitch.com and enter “Voyageur”
in the search box.
Rain Cage converts the CO2 into oxygen and carbon
and creates fullerene allotropes and nanotubes that can be applied
to a wide variety of products to enhance strength, durability and
with contrast materials, ease of delivery. Contrast materials,
which may be taken orally or rectally, are used to improve pictures
of the inside of the body helping to distinguish or "contrast"
selected areas of the body from surrounding tissue allowing the
radiologist to distinguish normal from abnormal conditions.
Everyone knows that carbon in its hardest form
creates a diamond, and in its softest form creates graphite such as
in a pencil. However, few know that it can also create a fullerene,
which is an allotrope of carbon with atoms connected to form a
closed, or partly closed mesh, that can potentially act as a
versatile delivery system for a wide range of biomedical
applications.
Fullerenes are biocompatible with the
nanostructures capable of being loaded with materials of medical
interest for diagnostic and therapeutic medicine. The major
hindrances to advancing new fullerene-based drugs are cost,
quality, and quantities of supply.
According to the NIH National Library of Medicine,
carbon allotropes have multiple applications in the pharmaceutical
industry for radiology contrast media, drug and gene delivery
systems, anti-viral and anti-bacterial medications,
photosensitizers, and can also be used as antioxidants. Medical
reports state that fullerene-based MRI contrast agents have
delivered a gain of 500-fold sensitivity versus conventional
contrast agents.
Voyageur and Rain Cage will work jointly to
develop new commercial fullerene molecules for contrast media
applications in medical imaging. Nuclear imaging will also be
explored as the two companies create the research and development
pathway for these new and novel drugs.
Fullerene based contrast media drugs will
potentially allow for much earlier detection of disease and
potentially provide a safer mechanism of transport, for toxic
metals to be deployed in the body, compared to current drugs that
are in the market.
Voyageur will deploy a Rain Cage carbon capture
unit at its new pharmaceutical manufacturing facility, scheduled
for construction in 2023, which will produce carbon for Voyageurs R
& D program and potential new drug production.
Voyageur has a vision to become 100% carbon
neutral and utilising Rain Cage carbon capture technologies will
play a significant role in achieving the milestone of creating
contrast materials that deliver a positive benefit for the
environment and contribute to the fight against climate change.
Voyageur is currently focused on the development
of barium, iodine, and carbon Active Pharmaceutical Ingredients and
high-performance cost-effective imaging contrast agents for the
medical radiology marketplace. The company owns a 100% interest in
three barium sulphate (barite) projects including the Frances Creek
property, suitable in grade for the pharmaceutical barite
marketplace, with additional interest in a high-grade iodine,
lithium & bromine brine project located in Utah, making the
company unique, as it sources its main ingredients from its own
mineral deposits
Voyageur is moving forward with its business plan
of becoming the only fully integrated company in the radiology
medical field, by controlling all primary input costs under the
motto of: "From the Earth to the Bottle".
The shares are currently trading at $0.09. For
more information, please visit www.VoyageurPharmaceuticals.ca,
contact Brent Willis, President and CEO, by email at
brent@vpharma.ca, or Al Deslauriers, CFO, at
albertl@vpharma.ca.
Disclaimer
The information in this InvestmentPitch Media Ltd
video is for the viewers information only. Voyageur Pharma has paid
a fee not exceeding $2,000 in cash to have its current news release
produced in video format. The corporate information is based on
information that is publicly available. Any information provided by
InvestmentPitch Media Ltd, through its media services is not to be
construed as a recommendation or suggestion or offer to buy or sell
securities but is provided solely as an informational media
service. InvestmentPitch Media Ltd makes no warranties or
undertakings as to the accuracy or completeness of this
information. All due diligence should be done by the viewer or
their financial advisor. Investing in securities is speculative and
carries risk.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of
video, which together with its extensive distribution, positions a
company’s story ahead of the 1,000's of companies seeking awareness
and funding from the financial community. The company specializes
in producing short videos based on significant news releases,
research reports and other content of interest to investors.
CONTACT: InvestmentPitch Media Barry Morgan, CFO
bmorgan@investmentpitch.com
Voyageur Pharmaceuticals (TSXV:VM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Voyageur Pharmaceuticals (TSXV:VM)
Historical Stock Chart
From Dec 2023 to Dec 2024